Accord Logo

Intended for UK patients and members of the public

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Pantoprazole Tablets

Active Ingredients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Pantoprazole 20mg Gastro-resistant Tablets

PL Number:
20075/0699
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Variation Description:

    IB C.I.2.a: to update sections 4.4, 4.5, 4.6 (40mg only), 4.8 and 5.2 for Pantoprazole 20 mg and 40 mg gastro-resistant tablets in line with the reference products Pantoprazole 20 mg, 40mg gastro-resistant tablets PL 16189/0034, 0035 (MAH: Takeda UK Limited) dated 18/07/2022.

    In addition, the PIL has been updated in line with the excipient guideline and QRD template.  The spelling of ‘Sodium lauryl sulfate’ has been corrected to ‘sodium laurilsulfate’ in PIL section 6.

    IB C.I.z: PIL section 2 for the above-listed MAs have been updated in line with the MHRA letter dated 16th December 2022 on reduced vitamin B12 absorption. The SPCs are not affected.

    SmPC sections updated: 4.4, 4.5, 4.6 (40mg only), 4.8, 5.2 and 10.

  • Variation Description:

    IB C.I.2.a: to update sections 4.4, 4.5, 4.6 (40mg only), 4.8 and 5.2 for Pantoprazole 20 mg and 40 mg gastro-resistant tablets in line with the reference products Pantoprazole 20 mg, 40mg gastro-resistant tablets PL 16189/0034, 0035 (MAH: Takeda UK Limited) dated 18/07/2022.

    In addition, the PIL has been updated in line with the excipient guideline and QRD template.  The spelling of ‘Sodium lauryl sulfate’ has been corrected to ‘sodium laurilsulfate’ in PIL section 6.

    IB C.I.z: PIL section 2 for the above-listed MAs have been updated in line with the MHRA letter dated 16th December 2022 on reduced vitamin B12 absorption. The SPCs are not affected.

    PIL sections updated: 2, 3, 4, 5 and 6.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Pantoprazole 40mg Gastro-resistant Tablets

PL Number:
20075/0700
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Variation Description:

    IB C.I.2.a: to update sections 4.4, 4.5, 4.6 (40mg only), 4.8 and 5.2 for Pantoprazole 20 mg and 40 mg gastro-resistant tablets in line with the reference products Pantoprazole 20 mg, 40mg gastro-resistant tablets PL 16189/0034, 0035 (MAH: Takeda UK Limited) dated 18/07/2022.

    In addition, the PIL has been updated in line with the excipient guideline and QRD template.  The spelling of ‘Sodium lauryl sulfate’ has been corrected to ‘sodium laurilsulfate’ in PIL section 6.

    IB C.I.z: PIL section 2 for the above-listed MAs have been updated in line with the MHRA letter dated 16th December 2022 on reduced vitamin B12 absorption. The SPCs are not affected.

    SmPC sections updated: 4.4, 4.5, 4.6 (40mg only), 4.8, 5.2 and 10.

  • Variation Description:

    IB C.I.2.a: to update sections 4.4, 4.5, 4.6 (40mg only), 4.8 and 5.2 for Pantoprazole 20 mg and 40 mg gastro-resistant tablets in line with the reference products Pantoprazole 20 mg, 40mg gastro-resistant tablets PL 16189/0034, 0035 (MAH: Takeda UK Limited) dated 18/07/2022.

    In addition, the PIL has been updated in line with the excipient guideline and QRD template.  The spelling of ‘Sodium lauryl sulfate’ has been corrected to ‘sodium laurilsulfate’ in PIL section 6.

    IB C.I.z: PIL section 2 for the above-listed MAs have been updated in line with the MHRA letter dated 16th December 2022 on reduced vitamin B12 absorption. The SPCs are not affected.

    PIL sections updated: 2, 3, 4, 5 and 6.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: